Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16:22 | ArriVent BioPharma: Oppenheimer bestätigt Rating trotz verzögerter Studiendaten | 2 | Investing.com Deutsch | ||
16:18 | ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating | 1 | Investing.com | ||
ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
14:30 | ArriVent expects topline data from lung cancer drug trial in early 2026 | 3 | Investing.com | ||
14:09 | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14:06 | ArriVent BioPharma, Inc.: ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 | 144 | GlobeNewswire (Europe) | Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent... ► Artikel lesen | |
10.07. | ArriVent BioPharma: Goldman Sachs startet Coverage mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
03.07. | ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval | 1 | Investing.com | ||
02.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
02.07. | ArriVent BioPharma prices $75M equity offering | 1 | Seeking Alpha | ||
02.07. | ArriVent BioPharma, Inc.: ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
01.07. | ArriVent BioPharma kündigt öffentliches Angebot von 75 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
01.07. | ArriVent announces $75M public offering | 1 | Seeking Alpha | ||
01.07. | ArriVent BioPharma announces $75 million public offering | 2 | Investing.com | ||
01.07. | ArriVent BioPharma, Inc.: ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
30.06. | ArriVent BioPharma-Aktie behält Kaufempfehlung von H.C. Wainwright nach starken NSCLC-Studiendaten | - | Investing.com Deutsch | ||
30.06. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data | 1 | Investing.com | ||
24.06. | Clear Street stuft ArriVent BioPharma-Aktie mit Kaufempfehlung ein | 2 | Investing.com Deutsch | ||
24.06. | Clear Street initiates ArriVent BioPharma stock with Buy rating | 3 | Investing.com | ||
23.06. | Citi erhöht Kursziel für ArriVent BioPharma nach positiven Lungenkrebsdaten | 3 | Investing.com Deutsch | ||
23.06. | Citi raises ArriVent BioPharma stock price target on lung cancer data | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,540 | +11,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
BIONTECH | 93,70 | -1,00 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
CRISPR THERAPEUTICS | 57,00 | +1,79 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
ITEOS THERAPEUTICS | 10,300 | +0,29 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
SAB BIOTHERAPEUTICS | 2,950 | +4,98 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
AVIDITY BIOSCIENCES | 34,920 | +3,50 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,230 | +2,41 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
180 LIFE SCIENCES | 3,220 | +71,28 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
SUMMIT THERAPEUTICS | 26,630 | +1,64 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
REDHILL BIOPHARMA | 2,820 | +46,11 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
ABSCI | 3,570 | +14,24 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
BRUKER | 30,540 | -12,49 % | Bruker-Aktie bricht nach Umsatzwarnung für Q2 ein | ||
VERVE THERAPEUTICS | 10,990 | +0,69 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |